These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 26965694)

  • 1. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
    Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
    Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
    Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
    Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
    Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
    Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
    Locatelli F; Hannedouche T; Fishbane S; Morgan Z; Oguey D; White WB
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1701-1710. PubMed ID: 31420350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginesatide in patients with anemia undergoing hemodialysis.
    Fishbane S; Schiller B; Locatelli F; Covic AC; Provenzano R; Wiecek A; Levin NW; Kaplan M; Macdougall IC; Francisco C; Mayo MR; Polu KR; Duliege AM; Besarab A;
    N Engl J Med; 2013 Jan; 368(4):307-19. PubMed ID: 23343061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
    Kacarska-Fotevska II; Volckova N; Ilievska K; Donev D
    Med Arch; 2020 Apr; 74(2):109-114. PubMed ID: 32577051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
    Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
    Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.
    Heidenreich S; Leistikow F; Zinn S; Baumann J; Atzeni A; Bajeski V; Dietzmann J; Dragoun GP;
    Clin Drug Investig; 2012 Feb; 32(2):99-110. PubMed ID: 22117178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.
    Locatelli F; Villa G; de Francisco AL; Albertazzi A; Adrogue HJ; Dougherty FC; Beyer U;
    Curr Med Res Opin; 2007 May; 23(5):969-79. PubMed ID: 17519064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
    Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
    Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.